These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 4566555)

  • 1. [Therapeutic experiences in multiple myeloma].
    Sonntag R; Favre E; Martz G
    Schweiz Med Wochenschr; 1972 Nov; 102(44):1588-9. PubMed ID: 4566555
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy of multiple myeloma. Review of the recent trials].
    Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
    Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma cell myeloma. An interpretive review.
    Bergsagel DE
    Cancer; 1972 Dec; 30(6):1588-94. PubMed ID: 4565818
    [No Abstract]   [Full Text] [Related]  

  • 5. [Recent progress in chemotherapy of multiple myeloma].
    Tortarolo M; Cantore N; Russolillo S; Castaldo C; Buonanno G
    Recenti Prog Med; 1978 Jul; 65(1):44-68. PubMed ID: 370935
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination chemotherapy for multiple myeloma.
    Alexanian R; Bonnet J; Gehan E; Haut A; Hewlett J; Lane M; Monto R; Wilson H
    Cancer; 1972 Aug; 30(2):382-9. PubMed ID: 5051662
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Kahler's disease].
    Foa J; Carcassonne Y
    Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results of plasmacytoma therapy of ALGB (acute leukemia group B)].
    Obrecht JP
    Hamatol Bluttransfus; 1976; 18():383-93. PubMed ID: 964714
    [No Abstract]   [Full Text] [Related]  

  • 11. The treatment of plasma cell myeloma.
    Bergsagel DE
    Br J Haematol; 1976 Aug; 33(4):443-9. PubMed ID: 795453
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of thalidomide in previously untreated patients with multiple myeloma.
    Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone healing in multiple myeloma with melphalan chemotherapy.
    Rodriguez LH; Finkelstein JB; Shullenberger CC; Alexanian R
    Ann Intern Med; 1972 Apr; 76(4):551-6. PubMed ID: 4640313
    [No Abstract]   [Full Text] [Related]  

  • 14. An overview of the status of the nitrosoureas in other tumors.
    Carter SK
    Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 17. [Reclassification of multiple myeloma and calculation of the myelomatous mass as prognostic and therapeutic indications].
    Ricci C; Coscia GC; Uberti M; Discalzi G; Racca P
    Recenti Prog Med; 1982 Apr; 72(4):482-99. PubMed ID: 7146598
    [No Abstract]   [Full Text] [Related]  

  • 18. Eastern cooperative oncology group studies.
    Lenhard RE
    Arch Intern Med; 1973 Mar; 131(3):418-20. PubMed ID: 4688039
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
    Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
    Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantable mouse plasma cell tumors in experimental chemotherapy.
    Teller MN; Abraham D; Bowie M; Carbone PP
    J Natl Cancer Inst; 1969 Jul; 43(1):123-31. PubMed ID: 5816022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.